記住我
LetterResearch LetterVascular biology
Open Access | 
10.1172/JCI166497
1Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
2Harvard Medical School, Boston, Massachusetts, USA.
3Division of Genetics,
4Undiagnosed Disease Network,
5Center for Genomic Medicine,
6Cardiovascular Genetics Program, and
7Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Mark E. Lindsay, Richard B. Simches Research Building, 3200 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: 617.643.3458; Email: Lindsay.Mark@mgh.harvard.edu.
Find articles by Lino Cardenas, C. in: JCI | PubMed | Google Scholar
1Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
2Harvard Medical School, Boston, Massachusetts, USA.
3Division of Genetics,
4Undiagnosed Disease Network,
5Center for Genomic Medicine,
6Cardiovascular Genetics Program, and
7Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Mark E. Lindsay, Richard B. Simches Research Building, 3200 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: 617.643.3458; Email: Lindsay.Mark@mgh.harvard.edu.
Find articles by Briere, L. in: JCI | PubMed | Google Scholar
1Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
2Harvard Medical School, Boston, Massachusetts, USA.
3Division of Genetics,
4Undiagnosed Disease Network,
5Center for Genomic Medicine,
6Cardiovascular Genetics Program, and
7Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Mark E. Lindsay, Richard B. Simches Research Building, 3200 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: 617.643.3458; Email: Lindsay.Mark@mgh.harvard.edu.
Find articles by Sweetser, D. in: JCI | PubMed | Google Scholar
1Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
2Harvard Medical School, Boston, Massachusetts, USA.
3Division of Genetics,
4Undiagnosed Disease Network,
5Center for Genomic Medicine,
6Cardiovascular Genetics Program, and
7Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Mark E. Lindsay, Richard B. Simches Research Building, 3200 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: 617.643.3458; Email: Lindsay.Mark@mgh.harvard.edu.
Find articles by Lindsay, M. in: JCI | PubMed | Google Scholar
1Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
2Harvard Medical School, Boston, Massachusetts, USA.
3Division of Genetics,
4Undiagnosed Disease Network,
5Center for Genomic Medicine,
6Cardiovascular Genetics Program, and
7Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Mark E. Lindsay, Richard B. Simches Research Building, 3200 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: 617.643.3458; Email: Lindsay.Mark@mgh.harvard.edu.
Find articles by
Musolino, P.
in:
JCI
|
PubMed
|
Google Scholar
|
Published January 17, 2023 - More info
Published in Volume 133, Issue 5 on March 1, 2023
To the Editor: Multisystemic smooth muscle dysfunction syndrome (MSMDS, OMIM #613834) is an ultrarare smooth muscle myopathy (1). Cases are monogenic from missense variation at arginine 179 of the ACTA2 gene (1, 2). Herein, we describe a case of MSMDS associated with a single-nucleotide variant in the gene MIR145.
Fetal ultrasound revealed polyhydramnios, enlarged abdomen and bladder, and prune belly syndrome. Profound gastrointestinal dysmotility was identified during infancy. His cerebrovascular disease began with frontal cortex and watershed strokes at approximately 2.5 years of age. Straightening of cerebral arteries and flattening of the genu of the corpus callosum and pons was observed. During school age he had multiple strokes consistent with arterial ischemic and watershed infarctions. Severe progressive steno-occlusive disease developed, which was worse in the anterior circulation (Figure 1, A and B). The vascular anatomy also showed straightening and decreased caliber of the terminal internal carotid artery, consistent with described cases of MSMDS (3, 4). Thoracic aortic imaging has been normal.
Figure 1Representative MRI T2-weighted FLAIR and maximum intensity projection (MIP) of MR angiography (MRA) images. (A) Images from a 36-month-old control and (B) 3 different time points of patient with miR-145-5p mutation. MRA images are anterior-posterior [AP] and lateral MIP. Note increased angulation of the forceps of the corpus callosum (red arrows) and significant bilateral periventricular and right watershed white matter injury (yellow arrows) at age 33 months, which progressed to bilateral white matter (yellow arrows) and right frontal ischemic infarctions (green arrows) by 8 years of age. Additional arterial ischemic infarctions occurred through 17 years of age. Vascular anatomy showed straightening and decreased caliber of the terminal internal carotid artery (ICA) and basal cerebral arteries with progression of the relative stenosis of the terminal ICA (red bar) when compared with its petrous segment. (C) Variant in the MIR145 gene shown as primary structure in multiple species comparison and in secondary structure. (D and E) Vascular SMCs transduced with indicated miRs, analyzed by Western blotting and immunofluorescence, demonstrate that the mutant version of miR-145-5p fails to mediate contractile protein expression or induce stress fiber formation similar to WT miR-145-5p. *Sequence conservation across species.
A thoracic aortic aneurysm/dissection panel was negative, including analysis of ACTA2. Quad genome sequencing was negative; however, research-based analysis revealed a de novo single-nucleotide variant in MIR145 (NR_029686.1: n.18C>A) (Figure 1C). This variant is absent from gnomAD, has a CADD score of 20.9, and MIR145 is enriched in tissues with high smooth muscle cell (SMC) content (5) (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI166497DS1). The MIR145 transcript is processed into 2 microRNAs (miRs), with the variant position at nucleotide 3 of miR-145-5p.
To determine whether the miR-145-5p variant could mediate the observed patient phenotype of smooth muscle dysfunction, we undertook molecular analysis. Cases of MSMDS to date have been caused by recurrent missense variants in the ACTA2 gene, altering arginine 179 (2). These variants impair α-smooth muscle actin (α-SMA) function, resulting in a cellular state resembling a loss of protein function. The miR-145-5p variant is located within the seed sequence (nt 2–8), the portion of a miR that stalls lateral diffusion of the RISC complex and promotes stable interactions with complementary RNAs (Figure 1C). We hypothesized that mutant miR-145-5p may not be able to target 3′ UTRs that mediate proper SMC function and may thus result in cellular changes similar to ACTA2 R179 variants. To assess this possibility, we exposed human vascular SMCs to an siRNA targeting miR-145-5p, wild-type (WT) miR-145-5p, or a mutant version of miR-145-5p with the patient variant. Indeed, transfection of either an siRNA against miR-145-5p or mutant miR-145-5p induced a notable decrease in the expression of several cytoskeletal proteins, including transgelin, calponin, and importantly, α-SMA (Figure 1D and Supplemental Figure 2; see complete unedited blots in the supplemental material).
Cellular models of the ACTA2 R179H mutation demonstrate global filamentous actin (F-actin) cytoskeletal deficiency (6). Transfection of either siRNA against miR-145-5p or the mutant miR-145-5p induced a phenotype characterized by deficient F-actin, whereas treatment with WT miR-145-5p enhanced stress fiber formation (Figure 1E). Therefore, we next performed RNA-seq analysis that included mRNAs and miRs in patient skin fibroblasts and compared them to WT skin fibroblasts. Principal component analysis of differentially expressed genes (DEGs) substantially differentiated the patient’s fibroblasts from control fibroblasts (Supplemental Figure 2). Furthermore, pathway analysis of DEGs showed enrichment of categories related to “hsa04810: regulation of actin cytoskeleton” (Supplemental Figure 3). Hybridization analysis and miR RNA-seq demonstrated a decrease in expression of miR-145-5p in the presence of mutant miR-145-5p (Supplemental Figures 1 and 4), consistent with impairment in a positive feedback loop for MIR145 expression (5).
In conclusion, genetic variation in the MIR145 gene expands the possible loci associated with MSMDS and further confirms the syndrome as a disorder of failed SMC development and function, although discovery of further cases will be necessary to confirm our findings. To our knowledge this is the first patient reported with a monogenic vascular disease caused by a mutation in a noncoding gene.
Supplemental material AcknowledgmentsWe would like to thank the patient and his family for their participation in this study and his home medical team for referring him to the Undiagnosed Disease Network study. This work was supported by the Caitlin and Rich Hill Family Fund for Undiagnosed Diseases and the NIH Common Fund under award number U01HG007690 (to DAS and LCB). MEL is supported by the Toomey fund for Aortic Dissection Research, PLM is supported by NIH grant R01NS117575, PLM and MEL are supported by NIH grant R01NS125353, and CLLC is supported by NIH grant K01HL164687.
Address correspondence to: Mark E. Lindsay, Richard B. Simches Research Building, 3200 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: 617.643.3458; Email: Lindsay.Mark@mgh.harvard.edu.
FootnotesConflict of interest: The authors have declared that no conflict of interest exists.
Copyright: © 2023, Lino Cardenas et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Submitted: October 25, 2022; Accepted: January 10, 2023; Published: March 1, 2023.
Reference information: J Clin Invest. 2023;133(5):e166497.
ReferencesMilewicz DM, et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A. 2010;152A(10):2437–2443. Regalado ES, et al. Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations. Genet Med. 2018;20(10):1206–1215. Munot P, et al. A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations. Brain. 2012;135(pt 8):2506–2514. Lauer A, et al. Cerebrovascular disease progression in patients with ACTA2 Arg179 pathogenic variants. Neurology. 2021;96(4):e538–e552. Cordes KR, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705–710. Lino Cardenas CL, et al. An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm. Nat Commun. 2018;9(1):1009. Version history Version 1 (January 17, 2023): In-Press Preview Version 2 (March 1, 2023): Electronic publication
留言 (0)